CD1c+ myeloid dendritic cells (mDCs) in the peripheral blood of 30 SHIV-SF162p4 and SIVmac251 sequentially infected Chinese rhesus macaques were examined by flow cytometry to obtain further insight into mDC alterations in HIV/AIDS. The CD1c+ cells were found to be mononuclear leukocytes rather than granulocytes, and most of them expressed CD20. CD1c+mDCs (CD1c+CD20-) consisted of two morphological subsets: the granular and the large CD1c+mDCs. The expression of HLA-DR, CD86, and CD11b, but no CCR7, CD83 and CD123, together with their endocytotic capacity indicated that they were immature mDCs. Their frequency at weeks 10 and 12 post-infection was significantly higher than that of un-infected ones; the large CD1c+mDC level was significantly different between time points and almost absent from un-infected rhesus monkeys; significant correlations between CD1c+mDCs and plasma viral load levels were also observed. These data indicated a possible role for CD1c+mDCs in the pathophysiological process of SIV/HIV infection.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cellimm.2011.05.017 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Human genital dendritic cell heterogeneity confers differential rapid response to HIV-1 exposure.
Front Immunol
November 2024
Department of Immunology, Tufts University School of Medicine, Boston, MA, United States.
Article Synopsis
- Dendritic cells (DCs) are crucial in understanding how HIV infects individuals, particularly in the female genital tract, which is a primary entry point for the virus.
- Researchers studied different types of genital DCs at the single cell level to see how they respond to HIV right after exposure.
- They discovered distinct DC subsets with unique responses: CD14+ DCs primarily triggered an antimicrobial response, while CD1c+ DC2s activated inflammasome pathways and interferon responses, highlighting potential strategies for preventing HIV infection.
Indeterminate DC histiocytosis is distinct from LCH and often associated with other hematopoietic neoplasms.
Blood Adv
November 2024
Department of Pathology, Ambroise-Paré Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), & EA4340-Biomarkers and clinical trials in Cancerology and Onco-Hematology, Versailles SQY University, Paris-Saclay University, Boulogne, France.
Article Synopsis
- Indeterminate dendritic cell histiocytosis (IDCH) is a rare condition marked by a buildup of specific histiocytes, with particular immunophenotypic features and clinical presentations, mostly in older adults.
- The study analyzed 43 cases, showing that many patients had skin or lymph node involvement, and a significant number had related blood cancers or other histiocytic diseases.
- Genetic analyses identified common mutations (like KRAS and BRAF) and unique gene fusions, helping to clarify IDCH's molecular profile and its potential impact on diagnosis and treatment strategies.
A randomized phase II clinical trial of stereotactic body radiation therapy (SBRT) and systemic pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c (BDCA-1)/CD141 (BDCA-3) myeloid dendritic cells in solid tumors.
Cancer Immunol Immunother
July 2024
Department of Medical Oncology, Laboratory for Medical and Molecular Oncology (LMMO), Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Laarbeeklaan 101, 1090, Brussels, Belgium.
Article Synopsis
- Radiotherapy combined with immune checkpoint blockade (ICB) is being tested in a clinical trial involving oligometastatic cancer patients to see if it can enhance T-cell responses and improve outcomes.
- In this phase II trial, patients were split into two groups: one receiving a combination of treatments immediately after radiotherapy (arm A) and a control group receiving pembrolizumab alone (arm B).
- Results showed a higher one-year progression-free survival rate in arm A (10%) compared to arm B (0%), but overall, the study did not meet its main goal of improving long-term survival outcomes.
Single-cell transcriptional profiling in osteosarcoma and the effect of neoadjuvant chemotherapy on the tumor microenvironment.
J Bone Oncol
June 2024
Department of Oncology, Second Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, China.
Osteosarcoma (OS), a malignant tumor, originates from the bone marrow. Currently, treatment for OS remains limited, making it urgent to understand the immune response in the tumor microenvironment of patients with OS. A comprehensive bioinformatics analysis was performed, including cell clustering subgroups, differential expression genes screening, proposed temporal order, and genomic variant analysis on single-cell RNA-sequencing data, from ten pre-chemotherapy patients and eleven post-chemotherapy patients.
View Article and Find Full Text PDF[Characterization of peripheral blood cellular populations in relation to Ascaris Lumbricoides infection in rural areas of Bolívar].
Rev Alerg Mex
February 2024
Profesor Honorario de Inmunología y Alergología, Director, Instituto de Investigaciones Inmunológicas, Universidad de Cartagena, Cartagena de Indias, Colombia.
Article Synopsis
- The study aimed to compare immune cell populations in the blood of infected (n=35) and uninfected (n=27) individuals from rural Bolívar, using specific diagnostic techniques and flow cytometry for analysis.
- Results showed no significant differences in age or sex between the two groups, with mild infections noted in cases and a slight decrease in neutrophil percentage among infected individuals, though the overall differences in immune cell types were minimal.
- The study was ethically approved, participants consented, and funding was provided through the Colombian Sistema General de Regalías.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!